1
|
Torres-Espin A, Rabadaugh H, Fitzsimons S, Harvey D, Chou A, Lindberg C, Casaletto KB, Goldberger L, Staffaroni AM, Maillard P, Miller BL, DeCarli C, Hinman JD, Ferguson AR, Kramer JH, Elahi FM. Sexually dimorphic differences in angiogenesis markers predict brain aging trajectories. bioRxiv 2023:2023.07.16.549192. [PMID: 37503183 PMCID: PMC10370093 DOI: 10.1101/2023.07.16.549192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/29/2023]
Abstract
Aberrant angiogenesis could contribute to cognitive impairment, representing a therapeutic target for preventing dementia. However, most angiogenesis studies focus on model organisms. To test the relevance of angiogenesis to human cognitive aging, we evaluated associations of circulating blood markers of angiogenesis with brain aging trajectories in two deeply phenotyped human cohorts (n=435, age 74 + 9) with longitudinal cognitive assessments, biospecimens, structural brain imaging, and clinical data. Machine learning and traditional statistics revealed sex dimorphic associations of plasma angiogenic growth factors with brain aging outcomes. Specifically, angiogenesis is associated with higher executive function and less brain atrophy in younger women (not men), a directionality of association that reverses around age 75. Higher levels of basic fibroblast growth factor, known for pleiotropic effects on multiple cell types, predicted favorable cognitive trajectories. This work demonstrates the relevance of angiogenesis to brain aging with important therapeutic implications for vascular cognitive impairment and dementia.
Collapse
|
2
|
Roseborough AD, Myers SJ, Khazaee R, Zhu Y, Zhao L, Iorio E, Elahi FM, Pasternak SH, Whitehead SN. Plasma derived extracellular vesicle biomarkers of microglia activation in an experimental stroke model. J Neuroinflammation 2023; 20:20. [PMID: 36721258 PMCID: PMC9890769 DOI: 10.1186/s12974-023-02708-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Accepted: 01/27/2023] [Indexed: 02/02/2023] Open
Abstract
Chronic microglia activation post-stroke is associated with worse neurological and cognitive outcomes. However, measurement of microglia activation in vivo is currently limited. Plasma derived extracellular vesicles (EVs) are cell-specific indicators that may allow for non-invasive measurement of microglia phenotype. The aim of this study was to identify activation-state specific microglia EVs (MEVs) in vitro followed by validation in an experimental stroke model. Following pro-inflammatory activation, MEVs contain the microglia protein TMEM119 alongside increased expression of the Toll-like receptor 4 co-receptor CD14. Immunoprecipitation followed by fluorescent nanoparticle tracking analysis (ONI Nanoimager) was used to confirm the isolation of TMEM119+/CD14+ EVs from rat plasma. Electron microscopy confirmed that TMEM119 and CD14 localize to the MEV membrane. To model ischemia, plasma was collected from 3-month wildtype Fischer344 rats prior to, 7 and 28 days after endothelin-1 or saline injection into the dorsal right striatum. Fluorescently labelled MEVs were directly measured in the plasma using nanoflow cytometry (Apogee A60 Microplus). We report a significant increase in circulating TMEM119+/CD14+ EVs 28-days post-stroke in comparison to baseline levels and saline-injected rats, which correlated weakly with stroke volume. TMEM119+/MHC-II+ EVs were also increased post-stroke in comparison to baseline and saline-injected animals. This study is the first to describe an EV biomarker of activated microglia detected directly in plasma following stroke and represents a future tool for the measurement of microglia activity in vivo.
Collapse
Affiliation(s)
- A. D. Roseborough
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - S. J. Myers
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - R. Khazaee
- grid.39381.300000 0004 1936 8884Biotron Integrated Microscopy Facility, The University of Western Ontario, London, ON Canada ,grid.39381.300000 0004 1936 8884Deparment of Biology, The University of Western Ontario, London, ON Canada
| | - Y. Zhu
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - L. Zhao
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| | - E. Iorio
- grid.266102.10000 0001 2297 6811Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA USA
| | - F. M. Elahi
- grid.266102.10000 0001 2297 6811Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA USA ,grid.59734.3c0000 0001 0670 2351Icahn School of Medicine at Mount Sinai, New York, USA ,grid.39381.300000 0004 1936 8884Department of Clinical Neurological Sciences, The Schulich School of Medicine and Dentistry, The University of Western Ontario, ON London, Canada
| | - S. H. Pasternak
- grid.59734.3c0000 0001 0670 2351Icahn School of Medicine at Mount Sinai, New York, USA ,grid.39381.300000 0004 1936 8884Department of Clinical Neurological Sciences, The Schulich School of Medicine and Dentistry, The University of Western Ontario, ON London, Canada ,grid.39381.300000 0004 1936 8884Robarts Research Institute, The Schulich School of Medicine and Dentistry, The University of Western Ontario, ON London, Canada
| | - S. N. Whitehead
- grid.39381.300000 0004 1936 8884Vulnerable Brain Laboratory, Department of Anatomy and Cell Biology, The Schulich School of Medicine and Dentistry, The University of Western Ontario, 458 Medical Sciences Building, ON N6A 3K London, Canada
| |
Collapse
|
3
|
Casaletto KB, Staffaroni AM, Wolf A, Appleby B, Brushaber D, Coppola G, Dickerson B, Domoto-Reilly K, Elahi FM, Fields J, Fong JC, Forsberg L, Ghoshal N, Graff-Radford N, Grossman M, Heuer HW, Hsiung GY, Huey ED, Irwin D, Kantarci K, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Litvan I, Mackenzie IR, Mendez M, Miller B, Rademakers R, Ramos EM, Rascovsky K, Roberson ED, Syrjanen JA, Tartaglia MC, Weintraub S, Boeve B, Boxer AL, Rosen H, Yaffe K. Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimers Dement 2020; 16:91-105. [PMID: 31914227 PMCID: PMC6953618 DOI: 10.1002/alz.12001] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Revised: 07/31/2019] [Accepted: 09/09/2019] [Indexed: 11/08/2022]
Abstract
INTRODUCTION Leisure activities impact brain aging and may be prevention targets. We characterized how physical and cognitive activities relate to brain health for the first time in autosomal dominant frontotemporal lobar degeneration (FTLD). METHODS A total of 105 mutation carriers (C9orf72/MAPT/GRN) and 69 non-carriers reported current physical and cognitive activities at baseline, and completed longitudinal neurobehavioral assessments and brain magnetic resonance imaging (MRI) scans. RESULTS Greater physical and cognitive activities were each associated with an estimated >55% slower clinical decline per year among dominant gene carriers. There was also an interaction between leisure activities and frontotemporal atrophy on cognition in mutation carriers. High-activity carriers with frontotemporal atrophy (-1 standard deviation/year) demonstrated >two-fold better cognitive performances per year compared to their less active peers with comparable atrophy rates. DISCUSSION Active lifestyles were associated with less functional decline and moderated brain-to-behavior relationships longitudinally. More active carriers "outperformed" brain volume, commensurate with a cognitive reserve hypothesis. Lifestyle may confer clinical resilience, even in autosomal dominant FTLD.
Collapse
Affiliation(s)
- K B Casaletto
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - A M Staffaroni
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - A Wolf
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - B Appleby
- Case Western Reserve University, Cleveland, Ohio, USA
| | | | - G Coppola
- University of California, Los Angeles, California, USA
| | - B Dickerson
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | | | - F M Elahi
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - J Fields
- Mayo Clinic, Rochester, Minnesota, USA
| | - J C Fong
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - L Forsberg
- Case Western Reserve University, Cleveland, Ohio, USA
| | - N Ghoshal
- Washington University, St. Louis, Illinois, USA
| | | | - M Grossman
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - H W Heuer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - G-Y Hsiung
- University of British Columbia, Vancouver, British Columbia, Canada
| | - E D Huey
- Columbia University, New York, New York, USA
| | - D Irwin
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | - D Kaufer
- University of North Carolina, Chapel Hill, North Carolina, USA
| | - D Kerwin
- University of Texas Southwestern, Dallas, Texas, USA
| | - D Knopman
- Mayo Clinic, Rochester, Minnesota, USA
| | - J Kornak
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA
| | - J H Kramer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - I Litvan
- Parkinson and Other Movement Disorder Center, Department of Neuroscience, University of California, San Diego, San Diego, California, USA
| | - I R Mackenzie
- University of British Columbia, Vancouver, British Columbia, Canada
| | - M Mendez
- University of California, Los Angeles, California, USA
| | - B Miller
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | | | - E M Ramos
- University of California, Los Angeles, USA
| | - K Rascovsky
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | | | | | - S Weintraub
- Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University, Chicago, Illinois, USA
| | - B Boeve
- Mayo Clinic, Rochester, Minnesota, USA
| | - A L Boxer
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - H Rosen
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - K Yaffe
- Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA
- San Francisco Department of Psychiatry, University of California, San Francisco, California, USA
| |
Collapse
|
4
|
Casaletto KB, Elahi FM, Fitch R, Walters S, Fox E, Staffaroni AM, Bettcher BM, Zetterberg H, Karydas A, Rojas JC, Boxer AL, Kramer JH. A comparison of biofluid cytokine markers across platform technologies: Correspondence or divergence? Cytokine 2018; 111:481-489. [PMID: 29908923 PMCID: PMC6289877 DOI: 10.1016/j.cyto.2018.05.032] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 04/12/2018] [Accepted: 05/29/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND Quantification of biofluid cytokines is a rapidly growing area of translational research. However, comparability across the expanding number of available assay platforms for detection of the same proteins remains to be determined. We aimed to directly compare a panel of commonly measured cytokines in plasma of typically aging adults across two high sensitivity quantification platforms, Meso Scale Discovery high performance electrochemiluminiscence (HPE) and single-molecule immunosorbent assays (Simoa) by Quanterix. METHODS 57 community-dwelling older adults completed a blood draw, neuropsychological assessment, and brain MRI as part of a healthy brain aging study. Plasma samples from the same draw dates were analyzed for IL-10, IP-10, IL-6, TNFα, and IL-1β on HPE and Simoa, separately. Reliable detectability (coefficient of variance (CV) < 20% and outliers 3 interquartiles above the median removed), intra-assay precision, absolute concentrations, reproducibility across platforms, and concurrent associations with external variables of interest (e.g., demographics, peripheral markers of vascular health, and brain health) were examined. RESULTS The proportion of cytokines reliably measured on HPE (87.7-93.0%) and Simoa (75.4-93.0%) did not differ (ps > 0.32), with the exception of IL-1β which was only reliably measured using Simoa (68.4%). On average, CVs were acceptable at <8% across both platforms. Absolute measured concentrations were higher using Simoa for IL-10, IL-6, and TNFα (ps < 0.05). HPE and Simoa shared only small-to-moderate proportions of variance with one another on the same cytokine proteins (range: r = 0.26 for IL-10 to r = 0.64 for IL-6), though platform agreement did not dependent on cytokine concentrations. Cytokine ratios within each platform demonstrated similar relative patterns of up- and down-regulation across HPE and Simoa, though still significantly differed (ps < 0.001). Supporting concurrent validity, all 95% confidence intervals of the correlations between cytokines and external variables overlapped between the two platforms. Moreover, most associations were in expected directions and consistently so across platforms (e.g., IL-6 and TNFα), though with several notable exceptions for IP-10 and IL-10. CONCLUSIONS HPE and Simoa showed comparable detectability and intra-assay precision measuring a panel of commonly examined cytokine proteins, with the exception of IL-1β which was not reliably detected on HPE. However, Simoa demonstrated overall higher concentrations and the two platforms did not show agreement when directly compared against one another. Relative cytokine ratios and associations demonstrated similar patterns across platforms. Absolute cytokine concentrations may not be directly comparable across platforms, may be analyte dependent, and interpretation may be best limited to discussion of relative associations.
Collapse
Affiliation(s)
- K B Casaletto
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States.
| | - F M Elahi
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - R Fitch
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - S Walters
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - E Fox
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - A M Staffaroni
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - B M Bettcher
- University of Colorado, Denver Anschutz Medical Center, 13001 E 17th Fl, Aurora, CO 80045, United States
| | - H Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska University Hospital, SE-43180 Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, SE-43180 Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom; UK Dementia Research Institute at UCL, London WC1N 3BG, United Kingdom
| | - A Karydas
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - J C Rojas
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - A L Boxer
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| | - J H Kramer
- Memory and Aging Center, University of California, San Francisco, Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158, United States
| |
Collapse
|
5
|
During EH, Osorio RS, Elahi FM, Mosconi L, de Leon MJ. The concept of FDG-PET endophenotype in Alzheimer's disease. Neurol Sci 2011; 32:559-69. [PMID: 21630036 DOI: 10.1007/s10072-011-0633-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2010] [Accepted: 05/13/2011] [Indexed: 01/05/2023]
Abstract
Often viewed as a potential tool for preclinical diagnosis in early asymptomatic stages of Alzheimer's disease (AD), the term "endophenotype" has acquired a recent popularity in the field. In this review, we analyze the construct of endophenotype-originally designed to discover genes, and examine the literature on potential endophenotypes for the late-onset form of AD (LOAD). We focus on the [18F]-fluoro-2-deoxyglucose (FDG) PET technique, which shows a characteristic pattern of hypometabolism in AD-related regions in asymptomatic carriers of the ApoE E4 allele and in children of AD mothers. We discuss the pathophysiological significance and the positive predictive accuracy of an FDG-endophenotype for LOAD in asymptomatic subjects, and discuss several applications of this endophenotype in the identification of both promoting and protective factors. Finally, we suggest that the term "endophenotype" should be reserved to the study of risk factors, and not to the preclinical diagnosis of LOAD.
Collapse
Affiliation(s)
- Emmanuel H During
- NYU Langone Medical Center, NYU School of Medicine, New York, NY, USA.
| | | | | | | | | |
Collapse
|